Open-Label Dose-Escalation Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Daily Oral MGCD265 Administered Without Interruption to Subjects With Advanced Malignancies

Trial Profile

Open-Label Dose-Escalation Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Daily Oral MGCD265 Administered Without Interruption to Subjects With Advanced Malignancies

Recruiting
Phase of Trial: Phase I

Latest Information Update: 05 Sep 2017

At a glance

  • Drugs Glesatinib (Primary)
  • Indications Gastric cancer; Prostate cancer; Solid tumours
  • Focus Adverse reactions
  • Sponsors MethylGene; Mirati Therapeutics
  • Most Recent Events

    • 29 Aug 2017 Planned End Date changed from 1 Aug 2017 to 1 Apr 2018.
    • 29 Aug 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Oct 2017.
    • 17 Jan 2017 Planned End Date changed from 1 Mar 2017 to 1 Aug 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top